Pancreas biopsy danger: who is at risk?

NCT ID NCT07168863

Recruiting now Knowledge-focused Sponsor: University of Tehran Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tracks 300 adults in Tehran who are getting a pancreas biopsy (EUS-guided FNB) to see how often pancreatitis occurs afterward. Researchers will measure enzyme levels 24 hours later and check for pain. The goal is to find out which factors—like age, gender, or biopsy location—raise the risk, so doctors can make the procedure safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors identify which patients are at higher risk for pancreatitis after a pancreas biopsy, leading to better prevention and safer procedures.
What could go wrong: This is an observational study, not a treatment trial. It will not test any new drug or therapy. The findings may not apply to other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EUS GUIDED BIOPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EUS GUIDED BIOPSY PANCREATITIS, ACUTE

Contacts and locations

Locations

Shariati Hospital, Digestive Diseases Research Institute
RECRUITING

Tehran, Tehran Province, 1411713135, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.